Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4)

PLoS Genetics

Volumn 10, Issue 10, 2014, Pages

  Key, Felix M ^a   Peter, Benjamin ^b   Dennis, Megan Y ^c   Huerta Sánchez, Emilia ^d   Tang, Wei ^e   Prokunina Olsson, Ludmila ^e   Nielsen, Rasmus ^b   Andrés, Aida M ^a  

^a MAX PLANCK INSTITUTE FOR EVOLUTIONARY ANTHROPOLOGY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON LAMBDA 4; INTERLEUKIN 29; UNCLASSIFIED DRUG; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

AFRICA; ALLELE; ARTICLE; ASIAN; BAYES THEOREM; DISEASE PREDISPOSITION; EUROPE; EUROPEAN; FRAMESHIFT MUTATION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PROTEIN FUNCTION; PSEUDOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; WESTERN HEMISPHERE; ANIMAL; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; CAUCASIAN; CONSERVED SEQUENCE; FAR EAST; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC SELECTION; GENETICS; HAPLOTYPE; HUMAN GENOME; MAMMAL; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POPULATION GENETICS; VIROLOGY;

AFRICA; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; BAYES THEOREM; CONSERVED SEQUENCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAR EAST; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOME, HUMAN; HAPLOTYPES; HEPATITIS C; HUMANS; INTERLEUKINS; MAMMALS; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSEUDOGENES; SELECTION, GENETIC;

EID: 84908335988     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004681     Document Type: Article

References (72)

1. Donnelly RP, Kotenko SV, (2010) Interferon-Lambda: A New Addition to an Old Family. Journal of Interferon & Cytokine Research 30: 555–564.
2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2002) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63–68.
3. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2002) IFN-θs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69–77.
4. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.
5. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.
7. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST, (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333–1342.
8. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP, (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529–538.
9. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud P, et al. (2011) Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than {IL28B} Genotype in Patients With Hepatitis C. Gastroenterology 140: 1021–1031.e10.
10. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, et al. (2010) Variants in {IL28B} in Liver Recipients and Donors Correlate With Response to Peg-Interferon and Ribavirin Therapy for Recurrent Hepatitis C. Gastroenterology 139: 1577–1585.e3.
11. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, et al. (2011) Interferon-lambda serum levels in hepatitis C. J Hepatol 54: 859–865.
12. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M, (2011) Genetic variation of the IL-28B promoter affecting gene expression. PLoS One 6: e26620.
13. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic {ISG} Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of {IFN} Therapy for Chronic Hepatitis C. Gastroenterology 139: 499–509.
14. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888–1896.
15. de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, et al. (2012) Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One 7: e31016.
16. Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, et al. (2011) Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome medicine 3: 57.
17. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45: 164.
18. Hamming OJ, Terczyńska-Dyla E, Vieyres G, Dijkman R, Jørgensen SE, et al. (2013) Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J
19. Aka P, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, et al. (2013) Association of the IFNL4-ΔG Allele with Impaired Spontaneous Clearance of Hepatitis C Virus. Journal of Infectious Diseases 32: 3055–65 doi: 10.1038/emboj.2013.232
20. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, et al. (2013) IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 210: 1109–1116.
21. Manry J, Laval G, Patin E, Fornarino S, Itan Y, et al. (2011) Evolutionary genetic dissection of human interferons. J Exp Med 208: 2747–2759.
22. Beaumont MA, Zhang W, Balding DJ, (2002) Approximate Bayesian computation in population genetics. Genetics 162: 2025–2035.
23. Peter B, Huerta-Sanchez E, Nielsen R, (2012) Distinguishing between Selective Sweeps from Standing Variation and from a De Novo Mutation. PLoS Genet 8: e1003011.
24. McVean GA, Altshuler (Co-Chair) DM, Durbin (Co-Chair) RM, Abecasis GR, Bentley DR, et al. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56–65.
25. Weir S, Cockerham CC, (1984) Estimating F-Statistics for the Analysis of Population Structure. Evolution 38: 1358.
26. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, et al. (2007) Genome-wide detection and characterization of positive selection in human populations. Nature 449: 913–918.
27. Voight BFAK, Wen SA, Pritchard XA, K J, (2006) A Map of Recent Positive Selection in the Human Genome. PLoS Biol 4: e72.
28. Fay JC, Wu CI, (2000) Hitchhiking under positive Darwinian selection. Genetics 155: 1405.
29. di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, et al. (2011) Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 53: 1446–1454.
30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41: 1100–1104.
31. Fu W, Akey JM, (2013) Selection and Adaptation in the Human Genome. Annu Rev Genomics Hum Genet 14: 467–89 doi: 10.1146/annurev-genom-091212-153509
32. Kass RE, Raftery AE, (1995) Bayes factors. Journal of the american statistical association 90: 773–795.
33. Jeffreys H (1998) The theory of probability. Oxford University Press.
34. Shebl FM, Pfeiffer RM, Buckett D, Muchmore B, Chen S, et al. (2011) IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. Journal of Infectious Diseases 204: 1843–1847 jir647.
35. Freeman A, (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34: 809–816.
36. Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, et al. (2014) The IFNL3/4 [DELTA]G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS [In Press].
37. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KCF, et al. (2013) Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling. Science 340: 207–211.
38. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, et al. (2013) Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection. Science 340: 202–207.
39. Olson MV, (1999) When less is more: gene loss as an engine of evolutionary change. Am J Hum Genet 64: 18.
40. McLean CY, Reno PL, Pollen AA, Bassan AI, Capellini TD, et al. (2011) Human-specific loss of regulatory DNA and the evolution of human-specific traits. Nature 471: 216.
41. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, et al. (2012) A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes. Science 335: 823–828.
42. Montgomery SB, Goode D, Kvikstad E, Albers CA, Zhang Z, et al. (2013) The origin, evolution and functional impact of short insertion-deletion variants identified in 179 human genomes. Genome Res 23: 749–61 doi: 10.1101/gr.148718.112
43. Yngvadottir B, Xue Y, Searle S, Hunt S, Delgado M, et al. (2009) A Genome-wide Survey of the Prevalence and Evolutionary Forces Acting on Human Nonsense {SNPs}. Am J Hum Genet 84: 224–234.
44. Frischmeyer PA, Dietz HC, (1999) Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 8: 1893–1900.
45. Andrés AM, Dennis MY, Kretzschmar WW, Cannons JL, Lee-Lin SQ, et al. (2010) Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation. PLoS Genet 6: e1001157.
46. Hamblin MT, Rienzo AD, (2000) Detection of the Signature of Natural Selection in Humans: Evidence from the Duffy Blood Group Locus. Am J Hum Genet 66: 1669–1679.
47. Wang XAG, Zhang WEA, Jianzhi (2006) Gene Losses during Human Origins. PLoS Biol 4: e52.
48. Xue Y, Daly A, Yngvadottir B, Liu M, Coop G, et al. (2006) Spread of an inactive form of caspase-12 in humans is due to recent positive selection. The American Journal of Human Genetics 78: 659–670.
49. MacArthur DG, Seto JT, Raftery JM, Quinlan KG, Huttley GA, et al. (2007) Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nat Genet 39: 1261–1265.
50. Seixas S, Ivanova N, Ferreira Z, Rocha J, Victor BL, (2012) Loss and Gain of Function in SERPINB11: An Example of a Gene under Selection on Standing Variation, with Implications for Host-Pathogen Interactions. PLoS One 7: e32518.
51. Tishkoff SA, Reed FA, Ranciaro A, Voight BF, Babbitt CC, et al. (2007) Convergent adaptation of human lactase persistence in Africa and Europe. Nat Genet 39: 31–40.
52. Thompson JD, Gibson T, Higgins DG, (2002) Multiple sequence alignment using ClustalW and ClustalX. Current protocols in bioinformatics Chapter 2. Unit 2.3. doi: 10.1002/0471250953.bi0203s00
53. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ, (2009) Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189–1191.
54. Yang Z, (2007) PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol 24: 1586–1591.
55. Paten B, Herrero J, Fitzgerald S, Beal K, Flicek P, et al. (2008) Genome-wide nucleotide-level mammalian ancestor reconstruction. Genome Res 18: 1829–1843.
56. Kvikstad EM, Duret L, (2014) Strong Heterogeneity in Mutation Rate Causes Misleading Hallmarks of Natural Selection on Indel Mutations in the Human Genome. Mol Biol Evol 31: 23–36.
57. Nielsen R, (2005) Molecular signatures of natural selection. Annu Rev Genet 39: 197–218.
58. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, et al. (2011) The variant call format and VCFtools. Bioinformatics 27: 2156–2158.
59. Grossman S, Andersen K, Shlyakhter I, Tabrizi S, Winnicki S, et al. (2013) Identifying Recent Adaptations in Large-Scale Genomic Data. Cell 152: 703–713.
60. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851–861.
61. Team RC (2011) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. Open access available at: http://cran.r-project.org
62. Hudson RR, (2002) Generating samples under a Wright–Fisher neutral model of genetic variation. Bioinformatics 18: 337–338.
63. Gravel S, Henn BM, Gutenkunst RN, Indap AR, Marth GT, et al. (2011) Demographic history and rare allele sharing among human populations. Proceedings of the National Academy of Sciences 108: 11983–11988.
64. Gutenkunst RNAH, Williamson RDA, Bustamante SHA, Carlos C, (2009) Inferring the Joint Demographic History of Multiple Populations from Multidimensional SNP Frequency Data. PLoS Genet 5: e1000695.
65. Ewing G, Hermisson J, (2010) MSMS: a coalescent simulation program including recombination, demographic structure and selection at a single locus. Bioinformatics 26: 2064–2065.
66. Wegmann D, Leuenberger C, Neuenschwander S, Excoffier L, (2010) Abctoolbox: a versatile toolkit for approximate bayesian computations. BMC Bioinformatics 11: 116.
67. Tajima F, (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123: 585.
68. Reynolds J, Weir BS, Cockerham CC, (1983) Estimation of the coancestry coefficient: basis for a short-term genetic distance. Genetics 105: 767–779.
69. Wegmann D, Leuenberger C, Excoffier L, (2009) Efficient approximate Bayesian computation coupled with Markov chain Monte Carlo without likelihood. Genetics 182: 1207–1218.
70. Tenenhaus M, (1998) La régression PLS: théorie et pratique. Editions Technip
71. Boulesteix A-L, Strimmer K, (2007) Partial least squares: A versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform 8: 32–44.
72. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, et al. (2013) The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus–induced microRNAs. Nat Immunol 15: 72–79.